U
SUPN icon

UBS’s Supernus Pharmaceuticals SUPN Stock Holding History

UBS’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$8K Buy
900
+100
+13% +$903 ﹤0.01% 9059
2014
Q2 		$9K Hold
800
– – ﹤0.01% 9004
2014
Q1 		$7K Buy
+800
New +$7.37K ﹤0.01% 9265
2013
Q3 		– Sell
-9,000
Closed -$58K – 10698
2013
Q2 		$58K Buy
+9,000
New +$53K ﹤0.01% 6554

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OHCM
Orchard Hill Capital Management New York $22.6M AUM 3.52% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS's SUPN Position: Q3 2014 in Review

UBS reduced its Supernus Pharmaceuticals (SUPN) stake by 7.6% in Q3 2014, selling an estimated $28.3K and leaving 38,035 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #4678.

UBS first reported a position in SUPN in Q2 2013 and has held it in 6 quarters since. The position peaked at $451K in Q2 2014. 93 funds tracked by Wall St. Rank hold SUPN as of Q3 2014.

  • UBS held 38,035 shares of Supernus Pharmaceuticals worth $330K as of Q3 2014.
  • UBS sold 3,136 Supernus Pharmaceuticals shares in Q3 2014, an estimated $28.3K.
  • Supernus Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4678 holding.
  • UBS first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Supernus Pharmaceuticals position peaked at $451K in Q2 2014.
  • 93 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.